Citius Oncology, Inc. CTOR Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s common stock, shares authorized (in shares)?
- Citius Oncology, Inc. (CTOR) reported common stock, shares authorized (in shares) of $400M in Q1 2026.
- How has Citius Oncology, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
- Citius Oncology, Inc.'s common stock, shares authorized (in shares) increased by 300.0% year-over-year, from $100M to $400M.
- What is the long-term trend for Citius Oncology, Inc.'s common stock, shares authorized (in shares)?
- Over 3 years (2022 to 2025), Citius Oncology, Inc.'s common stock, shares authorized (in shares) has grown at a 38.7% compound annual growth rate (CAGR), from $150M to $400M.